Lung Cancer — Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
Citation(s)
Phase I Study of Vandetanib (ZD 6474) and Bevacizumab Combination Therapy Evaluating the VEGF and EGF Signal Transduction Pathways in Adults With Solid Tumors and Lymphomas